Reference is made to the stock exchange release from SoftOx Solutions AS (the
"Company") on 25 March 2025 regarding the board resolution to increase the share
capital by carrying out a private placement and a debt conversion converting
outstanding claims to new shares in the Company.  

The new share capital following the completion of the share capital increase has
today been registered with the Norwegian Register of Business Enterprises.  

The new share capital of the Company is NOK 44 808 339,88 divided into  2 240
416 994 shares, each with a par value of NOK 0,02. 

About SoftOx Solutions AS:
SoftOx Solutions AS (SoftOx) is a pharmaceutical company listed on Euronext
Growth Oslo under 'SOFTX'. SoftOx Solutions AS was founded in 2012 and is
headquartered in Oslo. The SoftOx Solutions Group includes the holding company
SoftOx Solutions AS, the Malmö subsidiary Water Innovation AB (WIAB), and the
subsidiary SoftOx Defense Solutions AS. SoftOx is developing a highly effective
antimicrobial solution for use in biofilm, viral, and antimicrobial-resistant
infections. The patent-protected technology is based on extensive research and
development in partnership with leading Nordic research institutes. 

For more information on SoftOx, visit www.soft-ox.com